Cargando…

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer

BACKGROUND: Everolimus is a mTOR inhibitor used for the treatment of different solid malignancies. Many patients treated with the registered fixed 10 mg dose once daily are in need of dose interruptions, reductions or treatment discontinuation due to severe adverse events. This study determined the...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Wit, D., Schneider, T. C., Moes, D. J. A. R., Roozen, C. F. M., den Hartigh, J., Gelderblom, H., Guchelaar, H. J., van der Hoeven, J. J., Links, T. P., Kapiteijn, E., van Erp, N. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921118/ https://www.ncbi.nlm.nih.gov/pubmed/27169792 http://dx.doi.org/10.1007/s00280-016-3050-6

Ejemplares similares

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
por: Schneider, T. C., et al.
Publicado: (2015)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients
por: van Erp, Nielka P., et al.
Publicado: (2016)

Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients
por: Zwart, Tom C., et al.
Publicado: (2020)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers
por: van Rongen, A, et al.
Publicado: (2015)

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease
por: Krens, L. L., et al.
Publicado: (2017)

Regarding: ‘Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array’
por: Pander, J, et al.
Publicado: (2010)

Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation
por: van der Stoep, M. Y. E. C., et al.
Publicado: (2019)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Marginal increase of sunitinib exposure by grapefruit juice
por: van Erp, Nielka P., et al.
Publicado: (2010)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
por: Sanchez-Spitman, A. B., et al.
Publicado: (2021)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer
por: Pascual, Tomas, et al.
Publicado: (2017)

(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges
por: Schneider, Tatiana C., et al.
Publicado: (2016)

Genetic polymorphisms of 3′-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy
por: Sanchez-Spitman, A. B., et al.
Publicado: (2018)

Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array
por: Kweekel, D M, et al.
Publicado: (2009)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing
por: Yin, Anyue, et al.
Publicado: (2020)

Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer
por: Willemsen, A. E. C. A. B., et al.
Publicado: (2017)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Everolimus in Anaplastic Thyroid Cancer: A Case Series
por: Harris, Ethan J., et al.
Publicado: (2019)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

UGT1A1(*)28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
por: Kweekel, D M, et al.
Publicado: (2008)

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
por: Gietema, J. A., et al.
Publicado: (1995)

Everolimus- and sirolimus-eluting stents in patients with and without ST-segment elevation myocardial infarction
por: Velders, M. A., et al.
Publicado: (2014)

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
por: Deenen, Maarten J., et al.
Publicado: (2011)

The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients
por: Benoist, Guillemette E., et al.
Publicado: (2020)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
por: Bins, Sander, et al.
Publicado: (2018)

Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study
por: Moes, Dirk Jan A. R., et al.
Publicado: (2021)

Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients
por: Leegwater, E., et al.
Publicado: (2022)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

Thyroid Lobectomy for Low-Risk 1–4 CM Papillary Thyroid Cancer is not Associated with Increased Recurrence Rates in the Dutch Population with a Restricted Diagnostic Work-Up
por: Lin, J. F., et al.
Publicado: (2022)

Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study
por: Faggiano, A, et al.
Publicado: (2012)

IGF-I Influences Everolimus Activity in Medullary Thyroid Carcinoma
por: Gentilin, Erica, et al.
Publicado: (2015)

GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group
por: Kweekel, D M, et al.
Publicado: (2008)

Toxicity of culture material of Fusarium verticillioides strain MRC 826 to nonhuman primates.
por: Gelderblom, W C, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_a25ut227auoku6aorh5pau8jgo